Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report

WALTHAM, Mass.--(BUSINESS WIRE)--Mar 10, 2026-

2026 Antimicrobial Resistance Benchmark

The 2026 Antimicrobial Resistance Benchmark, published by the Access to Medicine Foundation, evaluates how pharmaceutical companies are addressing the global AMR crisis through research, access strategies, responsible antibiotic use, and manufacturing practices. The report finds that while some progress has been made—such as a few newly approved innovative antibiotics and modest improvements in product registrations in low- and middle-income cou…

AMR Benchmark 2026: Pharma efforts show progress, but superbugs still outpace innovation

Five years after the release of its previous Antimicrobial Resistance (AMR) Benchmark, the Access to Medicine Foundation finds bright spots in pharma’s efforts to tackle superbugs. However, drug resistance is outpacing industry-wide efforts. The challenge now is to urgently develop and apply approaches across more products and across more countries to mimimise this global threat and save lives. More than one million people die each year as a dir…